Arcutis Biotherapeutics reported a second-quarter profit and raised its full-year 2026 net product sales guidance. The company posted net income of $15.01 million, or $0.11 per share, compared with a loss of $15.89 million, or $0.13 per share, a year earlier. Total revenue rose to $129.86 million from $81.50 million, driven by higher demand for ZORYVE products and improved gross-to-net deductions. Arcutis now expects full-year net product sales of $525 million to $540 million, up from its prior forecast of $480 million to $495 million.
Arcutis Biotherapeutics IncQ2 profit and raised full-year sales guidance
